Synthesis and anti-human immunodeficiency virus type 1 activity of novel 3'-spiro nucleoside analogues of TSAO-T

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 6, 1997, Pages 507-517

  Alvarez, R ^a   Jimeno, M L ^a   Perez Perez M J ^a   De Clercq, E ^b   Balzarini, J ^b   Camarasa, M J ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

3' Spironucleosides; AIDS; HIV; Non nucleoside HIV 1 RT inhibitors; TSO T

Indexed keywords

NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TSAO T; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG PURIFICATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; PRIORITY JOURNAL; STEREOCHEMISTRY; VIRUS REPLICATION;

EID: 0030785190     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800604     Document Type: Article

References (32)

1. Alvarez R, Velázquez S, San-Félix A, Aquaro S, De Clercq E, Perno C-F, Karlsson A, Balzarini J & Camarasa MJ (1994) 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl-β-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″- oxathiole-2″,2″-dioxide) (TSAO) analogues. Synthesis and anti-HIV-1 activity. Journal of Medicinal Chemistry 37: 4185-4194.
2. Balzarini J, Pérez-Pérez MJ, San-Félix A, Schols D, Perno CF, Vandamme AM, Camarasa MJ & De Clercq E (1992a) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA 89: 4392-4396.
3. Balzarini J, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ & De Clercq E, (1992b) [2′,5′-bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 36: 1073-1080.
4. Balzarini J, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, Bathurst IC, Barr PJ & De Clercq E (1992c) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue 2′,5′-bis-O-(t-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) thymine (TSAO-T). Journal of Biological Chemistry 267: 11831-11838.
5. Balzarini J, Camarasa MJ & Karlsson A (1993a) TSAO derivatives: highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs of the Future 18: 1043-1055.
6. Balzarini J, Karlsson A, Vandamme AM, Pérez-Pérez MJ, Zhang H, Vrang L, Öberg B, Bäckbro K, Unge T, San-Félix A, Velázquez S, Camarasa MJ & De Clercq E (1993b) Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the novel class of HIV-1-specific TSAO nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors. Proceedings of the National Academy of Sciences, USA 90: 6952-6956.
7. Balzarini J, Velázquez S, Karlsson A, Pérez-Pérez MJ, San-Félix A, Camarasa MJ & De Clercq E (1993c) Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1 non-nucleoside analogues. Molecular Pharmacology 43: 109-114.
8. Balzarini J, Kleim JP, Riess G, Camarasa MJ, De Clercq E & Karlsson A (1994) Sensitivity of (138 GLU→LYS) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochemical and Biophysical Research Communications 201: 1305-1312.
9. 13C assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum NMR. Journal of the American Chemical Society 108: 2093-2094.
10. Boyer PL, Ding J, Arnold E & Hughes SH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 38: 1909-1914.
11. Calvo-Mateo A, Camarasa MJ, Díaz-Ortiz A & de las Heras FG (1988a) Novel aldol-type cyclocondensation of O-mesyl-(methyl-sulphonyl)-cyanohydrins. Application to the stereospecific synthesis of branched-chain sugars. Journal of the Chemical Society Chemical Communications 1114-1115.
12. Calvo-Mateo A, Camarasa MJ, Díaz-Ortiz A, de las Heras FG & Alemany A (1988b) Synthesis of 3′-C-cyano-3′-deoxypentofuranosylthymine nucleosides. Tetrahedron 44: 4895-4903.
13. Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J & De Clercq E (1992) 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-dioxide] pyrimidine nucleosides. Journal of Med-icinal Chemistry 35: 2721-2727.
14. Camarasa MJ, Pérez-Pérez MJ, Velázquez S, San-Félix A, Alvarez A, Ingate S, Jimeno ML, Karlsson A, De Clercq E & Balzarini J (1995) TSAO derivatives: highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides and Nucleotides 14: 585-594.
15. Cushley RJ, Watanabe KA & Fox JJ (1967) Nucleosides. XXXVIII. Proton magnetic resonance studies of acetylated nucleosides. Journal of the American Chemical Society 89: 394-400.
16. Garcia MV, Menéndez JC, Villacampa M & Söllhuber MM (1991) Study of the reaction between cyanohydrins and chlorosulfonyl isocyanate. A new, efficient method for the one-pot synthesis of 2,4-oxazolidinediones. Synthesis 697-698.
17. 179 in catalysis by deoxycytidilate from bacteriophage T4 examined by site-directed mutagenesis. Biochemistry 31: 10315-10321.
18. Hansske F, Madej D & Robins MJ (1984) 2′- and 3′-ketonucleosides and their arabino and xylo reduction products. Tetrahedron 40: 125-135.
19. 177 in Escherichia coli thymidylate synthase is a major determinant of pyrimidine specificity. Proceedings of the National Academy of Sciences, USA 89: 9725-9229.
20. Hayakawa H, Tanaka H, Itoh N, Nakajiwa M, Miyasaka T, Yamaguchi K & Iitaka Y (1987) Reaction of organometallic reagents with 2′- and 3′-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2′- and 3′-positions. Chemical and Pharmaceutical Bulletin 35: 2605-2608.
21. Ingate S, Pérez-Pérez MJ, De Clercq E, Balzarini J & Camarasa MJ (1995) Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-positions of the sugar moiety. Antiviral Research 27: 281-299.
22. 138→Lys on the p51 subunit. Journal of Biological Chemistry 269: 25255-25258.
23. Myers G, Korber B, Wain-Hobson S, Tehjeang K, Henderson L & Paolakis (Editors) (1994) Human Retroviruses and AIDS-1994. Los Alamos: Los Alamos National Laboratory.
24. Pérez-Pérez MJ, Camarasa MJ, Díaz-Ortiz A, San-Félix A & de las Heras FG (1991) Stereospecific synthesis of branched-chain sugars by a novel aldol-type cyclocondensation. Carbohydrate Research 216: 399-411.
25. Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E & Camarasa MJ (1992) TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl-β-D-ribofuranosyl]- 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-diox ide]pyrimidine and pyrimidine modified nucleosides. Journal of Medicinal Chemistry 35: 2988-2995.
26. Pérez-Pérez MJ, Balzarini J, De Clercq E & Camarasa MJ (1993) Glycosyl-oxycarbonylaminosulfonyl-2′,3′-dideoxynucleoside derivatives as lopophilic nucleotide mimics, synthesis and anti-HIV activity. Bioorganic and Medicinal Chemistry Letters 1: 279-284.
27. San-Félix A, Velázquez S, Pérez-Pérez MJ, Balzarini J, De Clercq E, Camarasa MJ (1994) Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-,5- and 6-substituted pyrimidine analogues. Journal of Medicinal Chemistry 37: 453-460.
28. Sarges R, Howard HR & Kelbaugh PR (1982) Synthesis of optically active spirohydantoins by asymmetric induction. Hydantoin formation from amino nitriles and chlorosulfonyl isocyanate. Journal of Organic Chemistry 47: 4081-4084.
29. 12 through the use of new two-dimensional NMR experiments. Journal of the American Chemical Society 108: 4285-4294.
30. Velázquez S, San-Félix A, Pérez-Pérez MJ, Balzarini J, De Clercq E & Camarasa MJ (1993) TSAO analogues. 3. Synthesis and anti-HIV-1 activity of [2′,5′-bis-O(tert-butyldimethylsilyl-β-D-ribofuranosyl]- 3′spiro-5′-[4′-amino-1″,2″-oxathiole-2″, 2″-dioxide] purine and purine-modified nucleosides. Journal of Medicinal Chemistry 36: 3230-3239.
31. Velázquez S, Jimeno ML, Camarasa MJ & Balzarini J (1994) Synthesis of [1-[3′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-arabino- and β-D-ribofuranosyl]cytosine]-2′-spiro-5″-(4″-amino- 1″,2″-oxathiole-2″,2″-dioxide) Tetrahedron 50: 11013-11022.
32. Witanowsky M, Stefaniak L & Webb GA (1993) Annual reports on NMR spectroscopy, vol. 25. Edited by GA Webb. London: Academic Press.